Botanix Pharmaceuticals Limited Sustainability Profile
Botanix Pharmaceuticals Limited, often referred to simply as Botanix, is an innovative biopharmaceutical company headquartered in Australia. Founded in 2016, the company focuses on developing novel therapies for skin diseases and other medical conditions, leveraging the therapeutic potential of cannabinoids. With a strong operational presence in Australia and the United States, Botanix is at the forefront of cannabinoid-based medicine. The company’s core products include its proprietary formulations designed to treat conditions such as acne and psoriasis, setting it apart in the competitive dermatology market. Botanix has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing cannabinoid research. With a growing portfolio and a focus on scientific excellence, Botanix Pharmaceuticals is positioned as a leader in the emerging field of cannabinoid therapeutics.
DitchCarbon Score
How does Botanix Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Botanix Pharmaceuticals Limited's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Botanix Pharmaceuticals Limited's reported carbon emissions
Botanix Pharmaceuticals Limited, headquartered in Australia, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Botanix Pharmaceuticals may still be in the early stages of developing a comprehensive sustainability strategy. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Botanix to establish clear climate commitments and reduction initiatives to align with industry standards and expectations.
How Carbon Intensive is Botanix Pharmaceuticals Limited's Industry?
How Carbon Intensive is Botanix Pharmaceuticals Limited's Location?
Botanix Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Botanix Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
